Bonilla Celia, Zurita Mercedes
Cell Therapy Unit, Puerta de Hierro Hospital, 28222 Majadahonda, Madrid, Spain.
Cell Therapy Unit Responsable, Puerta de Hierro Hospital, 28222 Majadahonda, Madrid, Spain.
Biomedicines. 2021 Jun 10;9(6):669. doi: 10.3390/biomedicines9060669.
Traumatic brain injury (TBI) represents physical damage to the brain tissue that induces transitory or permanent neurological disabilities. TBI contributes to 50% of all trauma deaths, with many enduring long-term consequences and significant medical and rehabilitation costs. There is currently no therapy to reverse the effects associated with TBI. An increasing amount of research has been undertaken regarding the use of different stem cells (SCs) to treat the consequences of brain damage. Neural stem cells (NSCs) (adult and embryonic) and mesenchymal stromal cells (MSCs) have shown efficacy in pre-clinical models of TBI and in their introduction to clinical research. The purpose of this review is to provide an overview of TBI and the state of clinical trials aimed at evaluating the use of stem cell-based therapies in TBI. The primary aim of these studies is to investigate the safety and efficacy of the use of SCs to treat this disease. Although an increasing number of studies are being carried out, few results are currently available. In addition, we present our research regarding the use of cell therapy in TBI. There is still a significant lack of understanding regarding the cell therapy mechanisms for the treatment of TBI. Thus, future studies are needed to evaluate the feasibility of the transplantation of SCs in TBI.
创伤性脑损伤(TBI)是指脑组织受到的物理损伤,可导致暂时性或永久性神经功能障碍。TBI占所有创伤死亡人数的50%,许多患者会承受长期后果,并产生巨大的医疗和康复费用。目前尚无治疗方法可逆转与TBI相关的影响。关于使用不同干细胞(SCs)治疗脑损伤后果的研究越来越多。神经干细胞(NSCs)(成人和胚胎来源)和间充质基质细胞(MSCs)在TBI的临床前模型以及引入临床研究中均显示出疗效。本综述的目的是概述TBI以及旨在评估基于干细胞的疗法在TBI中应用的临床试验状况。这些研究的主要目的是调查使用SCs治疗该疾病的安全性和有效性。尽管正在进行越来越多的研究,但目前可用的结果很少。此外,我们展示了我们关于在TBI中使用细胞疗法的研究。对于治疗TBI的细胞疗法机制仍存在重大认识不足。因此,未来需要进行研究以评估SCs移植在TBI中的可行性。